Epilepsy

During months 36 and 48 on open-label cenobamate treatment, 76.4% and 51.8% of patients achieved seizure reductions of at least 50% or 75%, respectively.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 24, 2022.

Kelly Knupp, MD, reviews available treatment options indicated for Dravet syndrome and shares her thoughts on the use of cannabidiol for patients.

Kelly Knupp, MD, leads a discussion on goals of treatment for patients who are earlier in their treatment journey.

Progress in therapeutics and diagnosis over the past decade has dramatically shifted the treatment landscape for this genetic epilepsy and rapidly advanced patient care.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement and related disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 17, 2022.

Dr Kelly Knupp, Dr Joseph E. Sullivan, and Mary Anne Meskis comment on the impact of Dravet syndrome on a patient and their caregiver’s quality of life and address education around SUDEP.

Kelly Knupp, MD, reviews the patient presentation of Dravet syndrome and the recognition of common signs and symptoms in patients.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Headache Society.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 10, 2022.

Kelly Knupp, MD; Joseph E. Sullivan, MD; and Mary Anne Meskis review diagnosis of Dravet syndrome and the role of genetic testing.

Kelly Knupp, MD, provides an overview of Dravet syndrome and shares insight on discerning the diagnosis of disease from febrile seizures.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 3, 2022.

The founder and chief medical officer of Omniscient Neurotechnology commented on the areas of need with understanding the brain map and treating conditions with multiple pathway crossover. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is World MS Day.

Neurology News Network for the week ending May 28, 2022.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 27, 2022.

David Evans, MBA, shared his experience from this year’s event and spoke about the progress that’s been made in advocating for patients in the last several years at the AAN's Neurology on the Hill conference.

In light of Tuberous Sclerosis Complex (TSC) Awareness Month throughout May, Kari Rosbeck, president and CEO, TSC Alliance, highlights what has been done to advance TSC research and how the organization is improving the diagnosis journey, access to care, and support for families.

The founder and chief medical officer of Omniscient Neurotechnology provided commentary on expanding the brain map, the use of advanced technology, and the need to familiarize clinicians with connectomics.

In total, 14% of those on antiseizure medication who did not receive periconceptional folic acid experienced preterm birth compared with 5% of those with supplementation.

Resective epilepsy surgery was generally associated with good outcomes regarding employment status, seizure reduction, and antiseizure medication reduction.